Stemline Therapeutics (NASDAQ: STML) and Five Prime Therapeutics (NASDAQ:FPRX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends and valuation.
Institutional and Insider Ownership
50.2% of Stemline Therapeutics shares are owned by institutional investors. Comparatively, 83.7% of Five Prime Therapeutics shares are owned by institutional investors. 16.7% of Stemline Therapeutics shares are owned by insiders. Comparatively, 6.5% of Five Prime Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
This table compares Stemline Therapeutics and Five Prime Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Five Prime Therapeutics||-408.42%||-41.57%||-35.39%|
Risk & Volatility
Stemline Therapeutics has a beta of -0.02, meaning that its stock price is 102% less volatile than the S&P 500. Comparatively, Five Prime Therapeutics has a beta of 3.91, meaning that its stock price is 291% more volatile than the S&P 500.
This is a summary of recent ratings and recommmendations for Stemline Therapeutics and Five Prime Therapeutics, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Five Prime Therapeutics||0||0||6||0||3.00|
Stemline Therapeutics presently has a consensus target price of $33.75, suggesting a potential upside of 139.36%. Five Prime Therapeutics has a consensus target price of $67.75, suggesting a potential upside of 219.73%. Given Five Prime Therapeutics’ higher possible upside, analysts clearly believe Five Prime Therapeutics is more favorable than Stemline Therapeutics.
Valuation & Earnings
This table compares Stemline Therapeutics and Five Prime Therapeutics’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Stemline Therapeutics||$1.04 million||342.87||-$38.30 million||($2.57)||-5.49|
|Five Prime Therapeutics||$30.69 million||19.97||-$65.69 million||($5.06)||-4.19|
Stemline Therapeutics has higher earnings, but lower revenue than Five Prime Therapeutics. Stemline Therapeutics is trading at a lower price-to-earnings ratio than Five Prime Therapeutics, indicating that it is currently the more affordable of the two stocks.
Five Prime Therapeutics beats Stemline Therapeutics on 8 of the 12 factors compared between the two stocks.
Stemline Therapeutics Company Profile
Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers. SL-401 consists of IL-3 recombinantly fused to a truncated diphtheria toxin payload. SL-701 is an immunotherapy designed to activate the immune system to attack tumors. SL-701 comprises various short synthetic peptides that correspond to epitopes of targets, including IL-13 receptor subunit alpha-2 (IL-13Ra2), ephrin type-A receptor 2 (EphA2) and survivin, present on brain cancer. SL-801 is an oral, small molecule that reversibly inhibits Exportin-1 (XPO1), also known as Chromosome Region Maintenance-1 (CRM-1), a nuclear transport protein.
Five Prime Therapeutics Company Profile
Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma. Its preclinical programs include FPA150, FPA154 and FPT155.
Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.